CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,331 enrolled
Drug / intervention
Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02158364
NCT02158364N/ACompleted
CompareCT.gov

Freeze-dried Live Attenuated Measles and Rubella Combined Vaccine "Takeda" Specified Drug-use Survey of Vaccinees After the Second Vaccination

Takeda·observational·Posted Jun 6, 2014·Updated Feb 23, 2018

In Brief

An observational study evaluating Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) for Measles/Rubella. Completed, enrolled 3,331 participants across 1 site.

Detailed Summary

The purpose of this survey is to assess the safety of freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) (freeze-dried live attenuated measles and rubella combined vaccine "Takeda") in terms of the occurrence of unknown/known adverse drug reactions and factors that may influence the safety of vaccinees after the second vaccination.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMeasles/Rubella
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 6, 2014
Enrollment StartMar 28, 2007
Primary CompletionFeb 20, 2011
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 12.1 years ago

Interventions

Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)drug

Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)